It was shown that the anti-CTLA-4 antibodies, currently used for the treatment of melanoma and lung cancer patients, significantly reduce the numbers of Tregs [52,53], and it is discussed if this is the mechanism how they actually activate the anti-tumor immune response. Here, CTLA4 is linked to melanoma.